CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
Hui LiuWen LeiChaoting ZhangChunmei YangJuying WeiQunyi GuoXiaojun GuoZhilu ChenYing LuKen H YoungZheming LuWenbin QianPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
This first-in-human study demonstrates the tolerability, safety, and encouraging efficacy of CD19-PD-1/CD28-CART in PD-L1+ large B-cell lymphoma.